Physician profile
Laura Mulka
NPI 1861493611
$305,818.90
in general payments reported to CMS, 2019-2025
66 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82K · 2022: $87K · 2023: $49K · 2024: $40K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Travel and Lodging: $26K · Food and Beverage: $13K · Consulting Fee: $8,567 · Education: $464 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,704.75 |
| Travel and Lodging | $25,615.30 |
| Food and Beverage | $12,776.78 |
| Consulting Fee | $8,566.50 |
| Education | $464.00 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $55,008.31 | 2021-2025 | Calquence, Imfinzi, Tagrisso |
| Genzyme Corporation | $52,129.94 | 2021-2025 | |
| Janssen Biotech, INC. | $39,918.78 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Sobi, INC | $36,992.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $34,066.44 | 2021-2025 | Reblozyl, Opdivo, Augtyro |
| Beigene USA, INC. | $26,205.08 | 2021-2025 | Brukinsa |
| Beone Medicines USA, INC. | $17,975.95 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $9,384.79 | 2021-2025 | Tecentriq, Venclexta, Phesgo |
| Epizyme, INC. | $8,824.78 | 2021-2022 | |
| Incyte Corporation | $8,052.96 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $6,270.57 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Cumberland Pharmaceuticals, INC. | $1,738.75 | 2025 | Sancuso |
| Ipsen Biopharmaceuticals, INC | $1,249.20 | 2021-2025 | Tazverik, Onivyde |
| Myriad Genetic Laboratories, INC. | $1,018.83 | 2021-2025 | Myrisk |
| Pfizer INC. | $664.00 | 2021-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $653.12 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Rigel Pharmaceuticals, INC. | $420.60 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Lilly USA, LLC | $382.17 | 2021-2025 | Verzenio, Mounjaro, Jaypirca |
| Novartis Pharmaceuticals Corporation | $375.52 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.36 | 2021-2025 | Iclusig, Fruzaqla, Hyqvia |
| Abbvie INC. | $346.79 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $320.11 | 2021-2025 | |
| Amgen INC. | $315.42 | 2021-2023 | Lumakras, Xgeva, Nplate |
| Astellas Pharma US INC | $301.06 | 2021-2025 | Xospata, Vyloy, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $262.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $219.16 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $210.22 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Geron Corporation | $161.03 | 2025 | Rytelo |
| Gilead Sciences, INC. | $159.50 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $135.42 | 2022-2025 | Injectafer, Enhertu |
| Eisai INC. | $123.10 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $116.46 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $105.84 | 2022-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Pharmaessentia USA Corporation | $99.85 | 2023-2025 | Besremi |
| Mirati Therapeutics, INC. | $90.95 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $87.77 | 2023-2025 | |
| Seagen INC. | $82.03 | 2021-2023 | Tukysa, Padcev |
| Coherus Oncology, INC. | $64.39 | 2023-2025 | Udenyca |
| Stemline Therapeutics INC. | $59.35 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $52.90 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $52.26 | 2024-2025 | |
| Taiho Oncology, INC. | $45.06 | 2021 | |
| Sumitomo Pharma America, INC. | $43.74 | 2023-2024 | Orgovyx |
| Exelixis INC. | $40.17 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $38.92 | 2024 | |
| Springworks Therapeutics, INC. | $38.35 | 2025 | Ogsiveo |
| Organon LLC | $38.17 | 2023 | Ontruzant |
| Janssen Pharmaceuticals, INC | $38.00 | 2023 | |
| Novocure INC. | $34.95 | 2024 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $33.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2021 | |
| Blueprint Medicines Corporation | $30.23 | 2023 | Ayvakit |
| Novo Nordisk INC | $23.68 | 2022 | |
| Adaptive Biotechnologies Corporation | $23.13 | 2021 | |
| Telix Pharmaceuticals | $22.26 | 2023 | Illuccix |
| Ge Healthcare | $21.19 | 2022 | |
| Genmab U.S., INC. | $21.01 | 2023 | Tivdak |
| Fennec Pharmaceuticals, INC. | $20.81 | 2024 | Pedmark |
| Relievant Medsystems, INC. | $20.51 | 2023 | Intracept |
| Emd Serono, INC. | $19.27 | 2021 | |
| Octapharma USA, INC. | $17.91 | 2023 | Panzyga |
| Deciphera Pharmaceuticals INC. | $17.81 | 2023 | Qinlock |
| Janssen Scientific Affairs, LLC | $15.93 | 2023 | Darzalex, Tecvayli |
| Progenics Pharmaceuticals, INC. | $15.23 | 2024 | |
| Biocon Biologics INC | $15.19 | 2025 | Ogivri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mulka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.